PWS Community Asked to Take Part in Nov. 4 FDA Virtual Meeting on LV-001

PWS Community Asked to Take Part in Nov. 4 FDA Virtual Meeting on LV-001

305947

PWS Community Asked to Take Part in Nov. 4 FDA Virtual Meeting on LV-001

The U.S. Food and Drug Administration (FDA) is holding a public advisory committee meeting regarding LV-101 (intranasal carbetocin) as a potential treatment of distress behaviors and insatiable hunger in Prader-Willi syndrome (PWS) patients. The Psychopharmacologic Drugs Advisory Committee meeting, to be held virtually Nov. 4 from 10 a.m. to 4 p.m. ET, represents a critical part of FDA’s reviewing process of LV-101, which was granted priority review in July. A decision on whether to approve its…

You must be logged in to read/download the full post.